

# COVITREM-1 - Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19

Head :GIBOT Sébastien

Last update : 05/06/2021 | Version : 1 | ID : 73586

## General

### Identification

Detailed name Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19

Sign or acronym COVITREM-1

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation NCT04544891

### General Aspects

Medical area Anesthesiology ? Intensive care  
Infectious diseases

Study in connection with Covid-19 Yes

Pathology (details) patients hospitalised due to Covid-19

Keywords biomarker, COVID-19

### Scientific investigator(s) (Contact)

Name of the director GIBOT

Surname Sébastien

Email s.gibot@chru-nancy.fr

Organization Nancy Regional University Hospital

### Collaborations

Participation in projects, networks and consortia Yes

## Funding

Funding status Public

Details BPI France

## Governance of the database

Sponsor(s) or organisation(s) responsible Nancy Regional University Hospital

Organisation status Public

Presence of scientific or steering committees Yes

## Additional contact

## Main features

## Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Another treatment or procedure

Database recruitment is carried out as part of an interventional study No

## Database objective

Main objective Evaluate the prognostic value of initial TREM-1 activation (first measurement collected) on clinical deterioration in patients hospitalised due to COVID-19 in medical, emergency and intensive care departments

Inclusion criteria Patients aged over 18 years  
Hospitalised for less than 3 days for any reason whatsoever, but screened for Covid-19. SARS-CoV-2 infection should be "probable" or "confirmed" according to the definition published on 3 April by Santé Publique France (French Public Health Agency): laboratory confirmation (by positive RT-PCR further to nasopharyngeal sample or any other

sample and/or positive serology indicating infection) or by a composite endpoint combining characteristic pulmonary impairment upon imaging and clinical/laboratory effects suggesting viral infection (including: fever, cough, chest pain, and biological inflammatory syndrome, lymphopenia, elevated liver enzymes).  
Registered with a social security scheme or a beneficiary of such a scheme  
The patient or their representative will have received information on the study and signed the emergency informed consent/inclusion form in compliance with Article L.1122-1-3 of the French Public Health Code (CSP)

## Population type

Age  
Adolescence (13 to 18 years)  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered Sick population

Pathology J96 - Respiratory failure, not elsewhere classified

Gender  
Male  
Woman

Geography area National

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY) 2020

### Size of the database

Size of the database (number of individuals) [1000-10 000[ individuals

Details of the number of individuals 1009

### Data

Database activity Current data collection

Type of data collected Clinical data

## Biological data

Clinical data (detail)	Direct physical measures
------------------------	--------------------------

Presence of a biobank	Yes
-----------------------	-----

Contents of biobank	Serum Plasma DNAc/RNAc
---------------------	------------------------------

Health parameters studied	Health event/morbidity Health event/mortality
---------------------------	--

## Procedures

Participant monitoring	Yes
------------------------	-----

Monitoring procedures	Monitoring by contact with the participant (mail, e-mail, telephone etc.)
-----------------------	---

Links to administrative sources	No
---------------------------------	----

## Promotion and access

### Promotion

### Access